Price
Frequently asked questions
What is Insulet's market capitalization?
What is Insulet's Price-to-Earnings (P/E) ratio?
What is the Earnings Per Share (EPS) for Insulet?
What are the analyst ratings and target price for Insulet's stock?
What is Insulet's revenue over the trailing twelve months?
What is the EBITDA for Insulet?
What is the free cash flow of Insulet?
What is the 5-year beta of Insulet's stock?
How many employees does Insulet have, and what sector and industry does it belong to?
What is the free float of Insulet's shares?
Financials
Market Cap
$18.70B5Y beta
1.20EPS (TTM)
$5.752Free Float
69.76MP/E ratio (TTM)
46.34Revenue (TTM)
$1.98BEBITDA (TTM)
$384.10MFree Cashflow (TTM)
$218.20MPricing
Analyst Ratings
The price target is $232.74 and the stock is covered by 21 analysts.
Buy
18
Hold
3
Sell
0
Information
Insulet Corporation is a medical device company. It is primarily engaged in the development, manufacture and sale of its continuous insulin delivery systems for people with insulin-dependent diabetes. The Omnipod System includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5), the Omnipod DASH Insulin Management System, the Omnipod Insulin Management System, and Omnipod GO. It also produces pods for Amgen for use in the Neulasta Onpro kit, a delivery system for Amgen's Neulasta. The Omnipod platform offers continuous insulin delivery that provides various benefits of insulin pump therapy in a way without the need for external tubing required with conventional pumps. The small, lightweight, self-adhesive disposable tubeless Omnipod device (Pod), can be worn in multiple locations, including the abdomen, hip, back of upper arm, upper thigh, or lower back, and delivers insulin into the body through a small flexible tube. Omnipod 5 includes an AID algorithm embedded in the Pod.
3,000
Medical Equipment & Supplies
Health Care
Identifier
ISIN
Primary Ticker